Neumora Therapeutics, Inc. Common Stock (NMRA)
USD 10.18
(-6.3%)
USD 10.18
(-6.3%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Cost of Revenue | 668 Thousand | 2.69 Million | 1.55 Million | - |
| Gross Profit | -668 Thousand | -2.69 Million | -1.55 Million | - |
| Operating Expenses | 187.52 Million | 135.87 Million | 237.32 Million | 95.51 Million |
| Selling, General and Administrative Expenses | 44.8 Million | 31.12 Million | 24.54 Million | 8.39 Million |
| Research and Development Expenses | 142.71 Million | 104.74 Million | 212.77 Million | 87.12 Million |
| Other Expenses | - | 405 Thousand | 11 Thousand | -3.75 Million |
| Cost and Expenses | 188.19 Million | 135.87 Million | 237.32 Million | 95.51 Million |
| Operating Income | -188.19 Million | -135.87 Million | -237.32 Million | -95.51 Million |
| Interest Expense | - | - | - | - |
| Income Tax Expense | 268 Thousand | -4.56 Million | 301.44 Thousand | -101.29 Thousand |
| Earnings before Tax | -235.65 Million | -130.9 Million | -237.31 Million | -99.27 Million |
| Net Income | -235.92 Million | -130.9 Million | -237.31 Million | -99.27 Million |
| Earnings Per Share Basic | -1.49 | -0.86 | -1.56 | -0.65 |
| Earnings Per Share Diluted | -1.49 | -0.86 | -1.56 | -0.65 |
| Weighted Average Shares Outstanding | 158.83 Million | 151.94 Million | 151.94 Million | 151.94 Million |
| Weighted Average Shares Outstanding (Diluted) | 158.83 Million | 151.94 Million | 151.94 Million | 151.94 Million |
| Gross Margin | - | - | - | - |
| EBIT Margin | - | - | - | - |
| Profit Margin | - | - | - | - |
| EBITDA | -187.52 Million | -135.27 Million | -236.78 Million | -95.41 Million |
| Earnings Before Tax Margin | - | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 160 Thousand | 158 Thousand | 668 Thousand | 166 Thousand | 1.02 Million | 991 Thousand |
| Gross Profit | -160 Thousand | -158 Thousand | -668 Thousand | -166 Thousand | -1.02 Million | -991 Thousand |
| Operating Expenses | 63.66 Million | 60.07 Million | 187.52 Million | 114 Million | 56.86 Million | 42.06 Million |
| Selling, General and Administrative Expenses | 15.03 Million | 14.31 Million | - | 11.23 Million | 15.26 Million | 9.29 Million |
| Research and Development Expenses | 48.62 Million | 45.75 Million | - | 102.76 Million | 41.6 Million | 32.76 Million |
| Other Expenses | -24 Thousand | -12 Thousand | 63.9 Million | -104 Thousand | -1000.00 | -39 Thousand |
| Cost and Expenses | 63.82 Million | 60.07 Million | 188.19 Million | 114 Million | 56.86 Million | 42.06 Million |
| Operating Income | -63.82 Million | -60.07 Million | -188.19 Million | -114 Million | -56.86 Million | -42.06 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | 125 Thousand | -6.36 Million | 268 Thousand | -5.37 Million | -4.01 Million | -3.55 Million |
| Earnings before Tax | -58.57 Million | -53.72 Million | -235.65 Million | -108.46 Million | -53.02 Million | -38.54 Million |
| Net Income | -58.7 Million | -53.72 Million | -235.92 Million | -108.73 Million | -53.02 Million | -38.54 Million |
| Earnings Per Share Basic | -0.37 | -0.34 | - | -0.68 | -0.34 | -0.25 |
| Earnings Per Share Diluted | -0.37 | -0.34 | - | -0.68 | -0.34 | -0.25 |
| Weighted Average Shares Outstanding | 158.98 Million | 157.94 Million | 158.83 Million | 158.83 Million | 155.39 Million | 151.95 Million |
| Weighted Average Shares Outstanding (Diluted) | 158.98 Million | 157.94 Million | 158.83 Million | 158.83 Million | 155.39 Million | 151.95 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -63.66 Million | -59.91 Million | - | -113.83 Million | -56.86 Million | -41.89 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
0IYS
300424
300792
000985
002104
SAFS